Cargando…

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

BACKGROUND: Breast cancer is the leading malignancy among Filipino women, with about 23.50% of cases characterized by human epidermal growth factor receptor-2 (HER2) overexpression. Trastuzumab, in addition to standard chemotherapy, is currently recommended as primary treatment for HER2-positive ear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Genuino, Anne Julienne, Chaikledkaew, Usa, Guerrero, Anna Melissa, Reungwetwattana, Thanyanan, Thakkinstian, Ammarin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873585/ https://www.ncbi.nlm.nih.gov/pubmed/31752849 http://dx.doi.org/10.1186/s12913-019-4715-8

Ejemplares similares

Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
por: Genuino, Anne Julienne, et al.
Publicado: (2019)

Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6
por: Due, Ong The, et al.
Publicado: (2019)

A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines
por: Guerrero, Anna Melissa, et al.
Publicado: (2015)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
por: Due, Ong The, et al.
Publicado: (2020)

Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2021)

Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences
por: Noparatayaporn, Prapaporn, et al.
Publicado: (2021)

Systematic Review and Meta-Analysis of Cost-effectiveness of Rotavirus Vaccine in Low-Income and Lower-Middle-Income Countries
por: Haider, Sabbir, et al.
Publicado: (2019)

Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis
por: Oranratnachai, Songporn, et al.
Publicado: (2021)

Meta-analysis of economic evaluation studies: data harmonisation and methodological issues
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2022)

Diagnostic performance of clinic and home blood pressure measurements compared with ambulatory blood pressure: a systematic review and meta-analysis
por: Karnjanapiboonwong, Auttakiat, et al.
Publicado: (2020)

A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy
por: Turongkaravee, Saowalak, et al.
Publicado: (2021)

Economic evaluation of hepatitis A vaccines by income level of the country: A systematic review
por: Gurav, Yogesh Kirshnarao, et al.
Publicado: (2022)

Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
por: Aungsumart, Saharat, et al.
Publicado: (2023)

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
por: Hajjar, Ali, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
por: Tran, Phuong T., et al.
Publicado: (2020)

Preventive Role of Diet Interventions and Dietary Factors in Type 2 Diabetes Mellitus: An Umbrella Review
por: Toi, Phung Lam, et al.
Publicado: (2020)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Economic evaluation of carbetocin as prophylaxis for postpartum hemorrhage in the Philippines
por: Briones, Jamaica Roanne, et al.
Publicado: (2020)

Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis
por: Leung, William, et al.
Publicado: (2016)

A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand
por: Tantai, Narisa, et al.
Publicado: (2014)

Economic evaluation of population-based type 2 diabetes mellitus screening at different healthcare settings in Vietnam
por: Toi, Phung Lam, et al.
Publicado: (2021)

Cost-Utility Analysis of Drug Treatments in Patients with Polypoidal Choroidal Vasculopathy in Thailand
por: Sangroongruangsri, Sermsiri, et al.
Publicado: (2021)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
por: Simoens, Steven, et al.
Publicado: (2021)

Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand
por: Chitpim, Natthakan, et al.
Publicado: (2022)

Targeted therapies in development for non-small cell lung cancer
por: Reungwetwattana, Thanyanan, et al.
Publicado: (2013)

Efficacy of anti-tuberculosis drugs for the treatment of latent tuberculosis infection: a systematic review and network meta-analysis
por: Yoopetch, Panida, et al.
Publicado: (2023)

Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome
por: Sangroongruangsri, Sermsiri, et al.
Publicado: (2021)

Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
por: Goldvaser, Hadar, et al.
Publicado: (2019)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2020)

Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma
por: Phruttinarakorn, Bantita, et al.
Publicado: (2020)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
por: Lluch-Gómez, J., et al.
Publicado: (2023)

Estimating the EQ-5D-5L value set for the Philippines
por: Miguel, Red Thaddeus D., et al.
Publicado: (2022)

Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis
por: Noviyani, Rini, et al.
Publicado: (2022)

Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis
por: Aungsumart, Saharat, et al.
Publicado: (2023)

Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer
por: Gershon, Noga, et al.
Publicado: (2019)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand
por: Leelahavarong, Pattara, et al.
Publicado: (2010)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kjchi4k5ilmlndsv4ifmc38eer